Centogene Receives Delisting Notice From Nasdaq

Centogene NV Receives Delisting Notice From Nasdaq

Centogene NV (Nasdaq: CNTG), a leading life science company focused on the development and commercialization of genomic and cell therapies, today announced that it has received a notification from Nasdaq's Listing Department notifying it of Nasdaq's determination to delist the company's common shares from the Nasdaq Global Market. Nasdaq's decision was based on the company's failure to maintain a minimum closing bid price of $1.00 per share for 30 consecutive trading days, as required under Nasdaq's listing rules.

Centogene Intends to Request a Hearing

Centogene intends to request a hearing with Nasdaq's Listing Qualifications Panel to appeal the delisting determination. The company believes that it has a strong business plan and that its shares continue to have value. Centogene is confident that it can regain compliance with Nasdaq's listing requirements and that it will be able to continue to be listed on the Nasdaq Global Market.

The delisting notice does not affect the company's operations or its ability to continue providing services to its customers. Centogene will continue to operate as a public company and its shares will continue to trade on the over-the-counter market if it is delisted from Nasdaq.